AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2021 Report on Fungal Keratitis (Ophthalmology) Drugs in Development - ResearchAndMarkets.com

July 9, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Jul 9, 2021--

The “Fungal Keratitis (Ophthalmology) - Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive information on the therapeutics under development for Fungal Keratitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fungal Keratitis and features dormant and discontinued projects.

ADVERTISEMENT

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

ADVERTISEMENT

  • The report provides a snapshot of the Global Therapeutic Landscape of Fungal Keratitis (Ophthalmology).
  • The report reviews pipeline therapeutics for Fungal Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development ranging from discovery till pre-registration.
  • The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities.
  • The report reviews key players involved in the development of Fungal Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The report assesses Fungal Keratitis (Ophthalmology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report summarizes all the dormant and discontinued pipeline projects.
  • The report reviews latest news related to pipeline therapeutics for Fungal Keratitis (Ophthalmology).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Fungal Keratitis (Ophthalmology).
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Fungal Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Indication - Overview
  • Indication - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Indication - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Indication - Companies Involved in Therapeutics Development
  • Company 1
  • Company 2
  • Company 3
  • Company XX
  • Indication - Drug Profiles
  • Drug 1 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug 2 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug 3 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug 4 - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug XX - Drug Profile
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Indication - Dormant Projects
  • Indication - Discontinued Products
  • Indication - Product Development Milestones
  • Featured News & Press Releases
  • Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ieadxh

View source version on businesswire.com:https://www.businesswire.com/news/home/20210709005298/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH OPTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 07/09/2021 10:32 AM/DISC: 07/09/2021 10:32 AM

http://www.businesswire.com/news/home/20210709005298/en